Managing GLP-1 Side Effects: What to Tell Your Patients

Side effects are the single biggest reason patients struggle with GLP-1 receptor agonist therapy. They are also, in most cases, manageable — if patients know what to expect and prescribers can intervene at the right time.

Gastrointestinal side effects

GI symptoms are by far the most common adverse effects of both semaglutide and tirzepatide. Understanding their timing and mechanism helps both prescribers and patients manage them effectively.

Nausea

Nausea is reported by 40–50% of patients at some point during treatment, making it the most frequent complaint. It is typically:

• Worst in the first two to four weeks at each dose level, then gradually improves as the body adapts
• Most intense one to three days after injection, coinciding with peak plasma drug concentrations
• Triggered by dose escalation — patients who tolerated 0.5 mg semaglutide well may experience renewed nausea when stepping up to 1.0 mg

What to tell patients:

• Eat smaller, more frequent meals rather than large portions
• Avoid fatty, greasy, or heavily spiced foods during the first week after a dose increase
• Stay well hydrated — sip water or clear fluids regularly throughout the day
• If nausea is significant, bland foods help: toast, rice, bananas, plain crackers (the BRAT diet)
• Eat slowly and stop at the first sign of fullness

Vomiting

Reported by approximately 10–25% of patients, particularly during titration. Isolated episodes are usually self-limiting. Persistent vomiting — more than two to three episodes per day or lasting beyond 48 hours — warrants clinical review and consideration of whether to delay dose escalation or temporarily reduce the dose.

Diarrhoea

Reported by around 15–20% of patients. Usually mild and transient. Advise patients to maintain fluid and electrolyte intake. If persistent, review dietary intake — patients sometimes compensate for reduced appetite by increasing high-fibre or sugar-free foods that can worsen symptoms.

Constipation

Affects roughly 10–15% of patients. Delayed gastric emptying — a core mechanism of GLP-1 drugs — naturally slows bowel transit. Combined with reduced food and fluid intake, constipation can become a significant quality-of-life issue.

What to tell patients:

• Maintain adequate fluid intake even when appetite is reduced — aim for at least 1.5 to 2 litres of water daily
• Include fibre-rich foods where tolerated
• Gentle physical activity supports bowel motility
• Over-the-counter osmotic laxatives (such as macrogol) can be used if needed — advise patients not to wait until constipation becomes severe before seeking help

Timing matters: the PK connection

A critical insight for managing side effects is their relationship to the pharmacokinetic (PK) cycle. Both semaglutide and tirzepatide reach peak plasma concentrations one to three days post-injection, then gradually decline towards trough levels before the next weekly dose.

This means side effects are not constant — they follow a predictable pattern:

• Days 1–3 post-injection: highest drug exposure, side effects most likely
• Days 4–5: gradual improvement as concentrations begin to fall
• Days 6–7: trough period, usually the most comfortable part of the cycle

When patients understand this pattern, they feel more in control. When prescribers can see it in real time — through daily check-in data mapped to the dosing cycle — they can differentiate between expected PK-related symptoms and genuine red flags.

Injection site management

Injection site reactions — redness, swelling, itching, or mild pain — are reported by a small percentage of patients. Practical advice includes:

• Rotate injection sites between the abdomen, thigh, and upper arm
• Allow the pen to reach room temperature before injecting (remove from the fridge 15–30 minutes prior)
• Clean the injection site but avoid alcohol wipes immediately before injection, as residual alcohol can cause stinging
• Apply gentle pressure after injection but avoid rubbing the site

Persistent or worsening injection site reactions should prompt a clinical review.

Red flags: when to escalate

Most GLP-1 side effects are self-limiting. However, prescribers should ensure patients know when to seek urgent advice:

• Severe, persistent abdominal pain radiating to the back — possible pancreatitis. This is rare but serious. Treatment should be stopped and the patient assessed urgently.
• Signs of dehydration — persistent vomiting or diarrhoea combined with reduced oral intake, dizziness, dark urine, or confusion. Particularly important in elderly patients or those on concomitant diuretics or SGLT2 inhibitors.
• Symptoms suggesting gallbladder disease — right upper quadrant pain, especially after eating. GLP-1 receptor agonists are associated with an increased risk of cholelithiasis.
• Allergic reactions — though rare, any signs of anaphylaxis or severe hypersensitivity require immediate medical attention.

Catching problems early

The challenge in real-world prescribing is that most side effects emerge between appointments. A patient who develops significant nausea on day two after their injection may not mention it until their next monthly review — by which point they may have already missed doses or decided to stop treatment.

This is where structured daily monitoring changes the equation. With Cadence, patients complete brief daily check-ins that capture symptom severity, adherence, and wellbeing. Prescribers see this data on their dashboard with automatic flagging of patients who may need early intervention. It turns reactive care into proactive support — exactly when patients need it most.

For prescribers looking to reduce dropout rates and improve patient outcomes on GLP-1 therapy, book a demo to see how Cadence works in practice.